Pharsight

Aveed patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718640 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
Mar, 2027

(2 years from now)

US8338395 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
May, 2027

(2 years from now)

Aveed is owned by Endo Pharms Inc.

Aveed contains Testosterone Undecanoate.

Aveed has a total of 2 drug patents out of which 0 drug patents have expired.

Aveed was authorised for market use on 05 March, 2014.

Aveed is available in injectable;intramuscular dosage forms.

Aveed can be used as testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; primary hypogonadism (congenital or acquired); hypogonadotropic hypogonadism (congenital or acquired)..

The generics of Aveed are possible to be released after 08 May, 2027.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 05, 2017

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 05 March, 2014

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...

Dosage: INJECTABLE;INTRAMUSCULAR

How can I launch a generic of AVEED before it's drug patent expiration?
More Information on Dosage

AVEED family patents

Family Patents